ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Dasatinib conjugated with cIAP1 recruiters were demonstrated to degrade BCR-ABL in BCR-ABL-positive chronic myeloid leukemia cells such as K562, KCL-22 and KU812 cells [30].